Strimpakos Alexios S, Syrigos Kostas N, Saif Muhammad Wasif
Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece.
JOP. 2012 Mar 10;13(2):177-9.
The current achievements in pancreatic cancer diagnosis and treatment are disappointing for patients and clinicians alike. Still, in the dawn of 2012, most patients are diagnosed at a late stage where cure is not feasible, with the majority going to succumb within the same year of diagnosis. Thus, the only hope for early and diagnosis and radical treatment is the invention of diagnostic and prognostic tests which might predict accurately patients who may develop this disease and those who have the most aggressive potential, so clinician adopt the appropriate strategy. In this paper we summarize the findings from the three most interesting research abstract as presented at the 2012 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. In particular, we focus on Abstract #160 which shows the diagnostic utility of microRNA serum profiling in pancreatic cancer patients, on Abstract #201 which suggests a potential prognostic role of transforming growth factor (TGF)-beta pathway in advanced pancreatic cancer, and on Abstract #165 which shows that protein S100A4 might be a new, potentially useful, predictive biomarker of gemcitabine efficacy.
目前胰腺癌诊断和治疗方面所取得的成果，无论是对患者还是临床医生而言，都令人失望。即便如此，在2012年初，大多数患者在确诊时已处于晚期，无法治愈，大多数患者会在确诊后的同一年内死亡。因此，实现早期诊断和根治性治疗的唯一希望在于发明诊断和预后检测方法，这些方法或许能够准确预测哪些患者可能罹患此病，以及哪些患者具有最强的侵袭性潜能，以便临床医生采取恰当的治疗策略。在本文中，我们总结了在2012年美国临床肿瘤学会胃肠道癌症研讨会上展示的三篇最具吸引力的研究摘要的研究结果。具体而言，我们重点关注摘要#160，其展示了微小RNA血清谱在胰腺癌患者中的诊断效用；关注摘要#201，其表明转化生长因子（TGF）-β通路在晚期胰腺癌中可能具有预后作用；关注摘要#165，其表明蛋白S100A4可能是吉西他滨疗效的一种新的、潜在有用的预测生物标志物。
